04 Sep Aurion Biotech
Posted at 15:54h
in
Arnaud Lacoste, CEO and Chief Scientific Officer
Oct. 5 | 5:45pm | FLW Ballroom F
Seattle, WA
(Private)
Aurion’s mission is to restore vision to millions of patients with life-changing regenerative therapies. Aurion is a commercial stage company in Japan and a clinical stage company in pivotal Phase 3 development in the U.S. In 2024, Aurion launched VyznovaTM, the first cell therapy for corneal endothelial disease commercially available in Japan. Aurion received the prestigious Prix Galien award for Best Start-Up in Biotech in 2022 and was named to Fast Company’s annual list of Most Innovative Companies in 2025. In 2025, Alcon acquired majority ownership of Aurion Biotech.